MEST Antibody

What is MEST antibody and what protein does it detect?

MEST antibody detects the Mesoderm-specific transcript homolog protein, also known as PEG1 (Paternally-expressed gene 1 protein). MEST belongs to the AB hydrolase superfamily and is an imprinting gene associated with growth of mesodermal origin cells . It plays significant roles in metabolic regulation through interactions with proteins such as PPARγ (Peroxisome proliferator-activated receptor gamma) and CEBPα (CCAAT/enhancer-binding protein alpha), highlighting its involvement in regulating adipocyte differentiation and metabolic functions .

What applications is MEST antibody validated for?

MEST antibody has been validated for multiple research applications across different experimental platforms. Based on comprehensive validation studies, the applications include:

This extensive validation across multiple techniques ensures researchers can confidently select the appropriate application for their specific experimental needs.

What is the typical reactivity profile of MEST antibody?

MEST antibody demonstrates reliable reactivity with samples from multiple species. Testing has confirmed:

Before applying the antibody to samples from other species, researchers should conduct pilot experiments to verify cross-reactivity, as sequence homology doesn't always guarantee epitope conservation or accessibility .

What molecular weight should I expect when detecting MEST protein?

When working with MEST antibody, it's important to note the discrepancy between theoretical and observed molecular weights:

• Calculated molecular weight: 38 kDa

• Observed molecular weight: 34 kDa

This difference is commonly observed and may be attributed to post-translational modifications, protein processing, or the specific isoform being detected. When analyzing Western blot results, the 34 kDa band should be considered the primary target for MEST detection.

What are the optimal dilutions for MEST antibody across different applications?

Proper antibody dilution is critical for achieving specific signals while minimizing background. The recommended dilutions for MEST antibody vary by application:

It is strongly recommended to titrate the antibody in each testing system to obtain optimal results, as the ideal concentration can vary based on sample type, fixation method, and detection system .

What controls should I include when using MEST antibody?

Including proper controls is essential for validating MEST antibody results. For robust experimental design, implement these controls:

• Input Control: Include whole lysate in Western blot to verify that the detection system works correctly. If the target signal appears in the lysate but not in the IP sample, it indicates that the antibody functions for detection but not for immunoprecipitation .

• Isotype Control: Use an IgG isotype matching the primary antibody class. For rabbit polyclonal antibodies, Normal Rabbit IgG is appropriate. This control helps identify any non-specific binding by antibodies of the same class .

• Bead-Only Control: For immunoprecipitation experiments, include samples with beads but no antibody to identify non-specific protein binding to the beads themselves .

• Positive Control: Use samples known to express MEST, such as human testis tissue, mouse testis tissue, or PC-3 cells, which have been confirmed positive for MEST expression .

• Knockdown/Knockout Validation: When possible, include MEST knockdown or knockout samples as the gold standard for antibody specificity validation .

These controls should be run alongside experimental samples for every experiment to ensure reliable interpretation of results.

What is the optimal antigen retrieval method for MEST antibody in IHC applications?

For optimal epitope accessibility in IHC applications with MEST antibody, the recommended antigen retrieval methods are:

• Primary Recommendation: TE buffer pH 9.0

• Alternative Method: Citrate buffer pH 6.0

The choice between these methods may depend on tissue type, fixation protocol, and tissue processing methods. For human pancreatic cancer tissue, which has been validated as a positive control for MEST antibody, the TE buffer method has shown reliable results . Researchers should systematically compare both methods on their specific tissue samples to determine which provides optimal signal-to-noise ratio.

How can I validate MEST antibody specificity for my research?

Validating antibody specificity is crucial for generating reliable research data. For MEST antibody, implement this comprehensive validation workflow:

• Positive and Negative Controls: Include tissues with known MEST expression (human testis, PC-3 cells) as positive controls and appropriate negative controls .

• Molecular Weight Verification: Confirm that detected bands appear at the expected molecular weight (34 kDa observed for MEST) .

• Multiple Detection Methods: Compare results across different techniques (WB, IHC, IF) when possible to ensure consistent detection patterns .

• Concentration Gradient: Test multiple antibody dilutions to identify the optimal concentration that maximizes specific signal while minimizing background .

• Genetic Validation: The gold standard for antibody validation is testing in knockdown or knockout systems. Published studies have demonstrated MEST antibody specificity using this approach .

• Signal-to-Noise Ratio Assessment: Quantitatively evaluate signal-to-noise ratio across different antibody concentrations to determine optimal working conditions .

• Antibody Competition: When available, perform peptide competition assays using the immunogen to confirm signal specificity.

Implementing these validation steps will substantially increase confidence in the specificity of your MEST antibody results.

What could cause non-specific bands in Western blots with MEST antibody?

Non-specific bands in Western blots can compromise data interpretation. When troubleshooting MEST antibody Western blots, consider these potential causes and solutions:

• Antibody Concentration: Excessive antibody can increase non-specific binding. Solution: Dilute the antibody further within the recommended range (1:500-1:1000) .

• Blocking Efficiency: Inadequate blocking allows antibody binding to non-target proteins. Solution: Optimize blocking time, temperature, and blocking agent concentration.

• Sample Preparation: Protein degradation can produce fragments detected as additional bands. Solution: Use fresh samples with appropriate protease inhibitors and maintain cold temperatures during processing.

• Cross-Reactivity: The antibody may recognize proteins with similar epitopes. Solution: Validate with knockout controls and try alternative MEST antibodies targeting different epitopes.

• Washing Protocol: Insufficient washing retains non-specifically bound antibodies. Solution: Increase washing duration or number of washes between incubation steps.

• Secondary Antibody Issues: Non-specific binding by secondary antibodies. Solution: Optimize secondary antibody dilution and include a secondary-only control.

Systematically addressing these factors will help resolve non-specific binding issues in MEST antibody Western blots.

How do I troubleshoot weak or absent signals in IHC with MEST antibody?

When confronting weak or absent signals in IHC with MEST antibody, follow this methodical troubleshooting approach:

• Antigen Retrieval Optimization: The selected method may be insufficient for your specific tissue. Solution: Compare the recommended TE buffer (pH 9.0) with alternative citrate buffer (pH 6.0), and optimize time and temperature parameters .

• Antibody Concentration: The antibody may be too dilute for your sample. Solution: Try higher concentrations within the recommended range (1:50-1:500) .

• Detection System Sensitivity: Your detection method may lack sufficient sensitivity. Solution: Switch to a more sensitive detection system or implement signal amplification techniques.

• Tissue Fixation: Overfixation can mask epitopes. Solution: Optimize fixation protocols or try different antigen retrieval methods.

• Endogenous Enzyme Activity: Incomplete quenching of endogenous peroxidase can reduce signal. Solution: Ensure proper blocking of endogenous enzyme activity before antibody application.

• Tissue-Specific Expression: MEST may be expressed at lower levels in your tissue than in validated positive controls. Solution: Compare with known positive control tissues (human testis or pancreatic cancer tissue) .

• Primary Antibody Incubation: Insufficient incubation time. Solution: Extend primary antibody incubation time, potentially including overnight incubation at 4°C.

Implementing these adjustments systematically will help identify and resolve factors limiting signal detection.

What are the best practices for protein A/G bead selection in MEST immunoprecipitation?

Selecting appropriate beads for MEST immunoprecipitation depends on the host species and antibody isotype. Follow these guidelines:

• Host Species Considerations: For rabbit-derived MEST antibodies, Protein A beads typically provide optimal binding efficiency. For mouse-derived antibodies, Protein G beads generally offer better affinity .

• Bead Type Selection: Choose between:

  • Agarose beads: Separated by centrifugation

  • Magnetic beads: Separated using a magnetic rack

  Both exhibit similar performance for IP, so selection can be based on laboratory equipment availability and workflow preferences .

• Handling Technique: When working with agarose beads, remove supernatant by careful pipetting rather than aspiration with vacuum to minimize bead loss .

• Pre-clearing Step: To reduce non-specific binding, pre-clear lysates with beads alone before adding the MEST antibody.

• Bead Capacity: Typical binding capacity is approximately 10-20 μg antibody per μL of packed beads. For MEST antibody IP, use 0.5-4.0 μg antibody for 1.0-3.0 mg of total protein lysate .

• Wash Buffer Optimization: Optimize salt and detergent concentrations in wash buffers to maintain specific interactions while reducing background.

Following these guidelines will enhance the specificity and efficiency of your MEST immunoprecipitation experiments.

How can I use MEST antibody to investigate adipocyte differentiation mechanisms?

MEST plays crucial roles in adipocyte differentiation through interactions with PPARγ and CEBPα . To investigate these mechanisms using MEST antibody:

• Expression Time-Course Analysis: Use Western blot with MEST antibody to track changes in MEST expression levels during adipocyte differentiation stages. This approach can establish temporal relationships between MEST expression and adipogenesis markers.

• Co-immunoprecipitation Studies: Employ MEST antibody for IP followed by Western blot detection of PPARγ and CEBPα to investigate protein-protein interactions during differentiation. This technique can reveal direct molecular associations between MEST and key adipogenic factors.

• Subcellular Localization: Implement immunofluorescence with MEST antibody to determine its subcellular distribution during different stages of adipocyte differentiation, potentially revealing translocation events associated with functional changes.

• Co-localization Analysis: Perform dual immunofluorescence with MEST antibody and markers of adipocyte differentiation to identify spatial relationships during the differentiation process.

• Functional Studies: Compare MEST expression patterns in normal versus differentiation-impaired adipocytes to establish connections between MEST levels and functional outcomes.

• Molecular Pathway Analysis: Combine MEST antibody detection with inhibitors of specific signaling pathways to determine which molecular mechanisms regulate MEST expression during adipogenesis.

These approaches provide complementary insights into the molecular mechanisms of MEST in adipocyte differentiation.

What methods can I use to quantify MEST expression across different tissue samples?

Accurate quantification of MEST expression requires appropriate methodologies and controls. Implement these strategies for reliable quantitative analysis:

These methodological approaches ensure reliable quantitative comparison of MEST expression across different experimental conditions and tissue types.

How does the difference between calculated (38 kDa) and observed (34 kDa) MEST molecular weight impact experimental interpretation?

The discrepancy between calculated (38 kDa) and observed (34 kDa) molecular weight of MEST has important implications for experimental design and data interpretation:

• Antibody Validation: When validating MEST antibody specificity, look for the 34 kDa band rather than expecting a band at the calculated 38 kDa position. This prevents false negative interpretation when the antibody is actually detecting the correct protein.

• Possible Biological Explanations:

  • Post-translational processing (signal peptide cleavage or proteolytic processing)

  • Alternative splicing producing a smaller isoform

  • Differential protein folding affecting gel migration

  • Post-translational modifications altering apparent molecular weight

• Experimental Verification Approaches:

  • Mass spectrometry analysis to confirm protein identity and exact mass

  • Use multiple MEST antibodies targeting different epitopes to verify consistent detection

  • Compare with recombinant MEST protein of known molecular weight

• Reporting Considerations: When documenting MEST detection in publications, clearly specify both the calculated and observed molecular weights to prevent confusion and facilitate cross-laboratory comparisons.

Understanding this discrepancy is critical for accurate interpretation of Western blot results and antibody validation experiments involving MEST protein.

What are the key considerations for using MEST antibody in multi-protein co-localization studies?

When designing multi-protein co-localization studies with MEST antibody, consider these methodological factors:

• Antibody Compatibility: Ensure primary antibodies are from different host species (e.g., rabbit anti-MEST with mouse anti-PPARγ) to prevent cross-reactivity of secondary antibodies. If using antibodies from the same species, implement sequential staining protocols with appropriate blocking steps.

• Fluorophore Selection: Choose fluorophores with minimal spectral overlap to reduce bleed-through artifacts. Implement appropriate single-color controls to verify spectral separation.

• Fixation Optimization: Different proteins may require different fixation methods for optimal epitope preservation. Test multiple fixation protocols to identify conditions compatible with all target proteins.

• Order of Detection: The order of antibody application can impact signal intensity and specificity. Test different sequences to determine optimal protocol.

• Confocal Microscopy Settings: Carefully adjust acquisition parameters to minimize photobleaching while maintaining sufficient signal-to-noise ratio. Implement sequential scanning when possible to eliminate cross-talk.

• Quantitative Co-localization: Use appropriate software and statistical methods for quantifying co-localization:

  • Pearson's correlation coefficient

  • Manders' overlap coefficient

  • Object-based co-localization analysis

• Controls for Co-localization: Include appropriate controls such as known co-localizing and non-co-localizing proteins to validate your co-localization analysis pipeline.

Following these guidelines will enhance the reliability of multi-protein co-localization studies involving MEST antibody.

How should I present MEST antibody data in scientific publications?

When presenting MEST antibody data in publications, follow these best practices to ensure reproducibility and transparency:

• Antibody Documentation: Include complete antibody information:

  • Manufacturer and catalog number

  • Clone name for monoclonal antibodies

  • Host species and antibody type (monoclonal/polyclonal)

  • RRID (Research Resource Identifier) when available (e.g., AB_2143740 for certain MEST antibodies)

• Protocol Details: Provide comprehensive methodological information:

  • Dilutions used for each application

  • Incubation times and temperatures

  • Antigen retrieval methods for IHC/IF

  • Detection systems and imaging parameters

  • Software used for image analysis

• Controls Documentation: Describe all controls implemented:

  • Positive and negative controls

  • Isotype controls

  • Validation approaches (e.g., knockdown verification)

• Representative Images: Include full, unmanipulated images with appropriate scale bars. When presenting cropped images, indicate this in the figure legend.

• Quantification Methods: Clearly describe quantification approaches:

  • Normalization methods

  • Number of technical and biological replicates

  • Statistical tests applied

  • Software used for analysis

• Limitations Discussion: Acknowledge any limitations of the antibody or detection methods in the discussion section.

Following these reporting guidelines enhances transparency and facilitates experimental reproduction by other researchers.

How can I integrate MEST antibody data with genomic and transcriptomic information?

Integrating MEST antibody data with genomic and transcriptomic datasets provides multi-dimensional insights. Implement these approaches for comprehensive analysis:

• Protein-mRNA Correlation: Compare MEST protein levels detected by antibody with MEST mRNA expression to identify potential post-transcriptional regulation mechanisms. Discrepancies between protein and mRNA levels may indicate regulatory processes worth investigating.

• Genomic Context Integration: Correlate MEST protein expression with genomic features:

  • DNA methylation status of the MEST gene (relevant due to its imprinting status)

  • Copy number variations affecting MEST locus

  • Single nucleotide polymorphisms in regulatory regions

• Multi-Omics Data Visualization: Implement integrated visualization tools that allow simultaneous display of protein, transcript, and genomic data in a unified interface.

• Pathway Analysis: Place MEST antibody data in broader biological context by integrating with pathway databases to identify functional networks and potential regulatory mechanisms.

• Cell Type Deconvolution: For tissue samples, correlate MEST protein expression with cell type composition inferred from transcriptomic data to identify cell type-specific expression patterns.

• Statistical Integration Approaches:

  • Canonical correlation analysis

  • Partial least squares regression

  • Network-based integration methods

• Temporal Dynamics: When possible, collect time-series data to correlate changes in MEST protein expression with transcriptional programs during biological processes.

These integrative approaches enhance the biological significance of MEST antibody data beyond single-protein analysis.